Stockholders elect Jon Congleton as Class I director and ratify Ernst & Young as auditor at 2024 annual meeting

Mineralys Therapeutics, Inc.

Proposal 1: Jon Congleton elected as Class I director with 26,418,385 votes for, 3,775,533 withheld, 1,838,014 broker non-votes.
Proposal 2: Ratification of Ernst & Young as independent auditor approved with 32,025,366 for, 1,187 against, 5,379 abstain.
Annual meeting held May 22, 2024; both proposals passed with requisite votes.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.